Blood markers for acute b lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks if two natural substances in your blood (called cytokines) are linked to how active your leukemia is. It aims to help doctors better understand and possibly predict the disease, which could guide future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have just been diagnosed with acute B lymphoblastic leukemia.
- You must not have received chemotherapy or immunotherapy for this leukemia.
- You must not have any other type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help predict outcomes in patients with newly diagnosed acute leukemia. The test measures the ratio of two proteins in your blood, which might give doctors clues about how the disease will progress.
This study looks at routine blood test results (called CBC) in people who have just been diagnosed with acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if certain blood levels can help doctors understand the disease better and guide treatment.
This study looks at certain markers on your blood cancer cells to understand them better. By joining, you help doctors learn more about your disease, which may guide future care.
This study looks at certain proteins on B-cell blood cancer cells to understand them better. It may help doctors learn more about these cancers, but it is not a treatment trial.
This study looks at two simple blood tests in people newly diagnosed with ALL (a type of blood cancer) to see if these tests can help predict how the disease might progress. It may help doctors understand your condition better and could lead to more personalized care.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Hear when a new Acute Lymphoblastic Leukemia, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.